Citations

Clear

8 citation(s) found for "Collins, Gary".

Initial versus Subsequent Injury and Illness and Temporal Trends Among Professional Hockey Players
Martin, Chelsea , Lieb, Allison, Tokish, John M. , Shanely, Ellen, Kluzek, Stefan , Collins, Professor Gary S. , Tokish, John, Collins, Gary , Bullock, Garrett S.

Mayo Clinic

International Journal of Sports Physical Therapy | February 1, 2024 | Volume: 19 | Issue: 2 | Pages: No page available

10.26603/001c.92309 | PMID 38313661 Get It

Background Research is limited investigating injuries/illness incidence among National Hockey League (NHL) players. This study sought to establish injury/illness incidence, initial versus subsequent injury risk among NHL players, and determine temporal trends of injury and illness incidence. Hypothesis Variations in injury incidence by body region, and initial versus subsequent injury would be observed among positions. Study Design Retrospective cohort study Methods Publicly available data were utilized. NHL players 18 years or older between 2007-2008 to 2018-2019 were included. Injury and illness was stratified by position and body segment. Incidence rate (IR), and initial versus subsequent injury and illness risk ratios were calculated. Temporal trends were reported. Results Nine thousand, seven-hundred and thirty four injuries and illnesses were recorded. Centers had the highest overall IR at 15.14 per 1000 athlete game exposures (AGEs) (95%CI:15.12-15.15) and were 1.4 times more likely to sustain a subsequent injury compared to other positions. The groin/hip/thigh was the most commonly injured body region with an IR of 1.14 per 1000 AGEs (95%CI:1.06-1.21), followed by the head/neck (0.72 per 1000 AGEs, 95%CI:0.66-0.78). Combined injury and illness IR peaked in 2009-2010 season at 12.01 (95%CI: 11.22-12.79). The groin/hip/thigh demonstrated peak incidence during the 2007-2008 season (2.53, 95%CI:2.17-2.90); head/neck demonstrated a peak incidence in 2010-2011 season (Overall: 1.03, 95%CI:0.81-1.26). Injuries reported as ‘lower body’ increased over time. Conclusions Positional differences were observed; centers demonstrated the highest overall IR, and subsequent injury risk. Injury by body region was similar to previous literature. Head/neck and concussion decreased over time supporting rule changes in body checking and visor wear. Clinicians should be aware that ‘lower body’ injuries increased over time; therefore, injuries to the groin/hip/thigh or knee are likely underreported. Level of Evidence Level 3
Prognostic Biomarkers in Kidney Transplantation: A Systematic Review and Critical Appraisal
Raynaud, Marc , Awadhi, Solaf Al, Louis, Kévin , Zhang, Huanxi , Su, Xiaojun , Goutaudier, Valentin , Wang, Jiali, Demir, Zeynep , Wei, Yongcheng , Truchot, Agathe , Bouquegneau, Antoine , Bailly, É. , Maanaoui, Mehdi , Naser, Sofía , Wang, Changxi , Liu, Longshan , Lefaucheur, Carmen , Riella, Leonardo V. , Collins, Professor Gary S. , Al-Awadhi, Solaf , Bailly, Élodie , Lombardi, Yannis , Giarraputo, Alessia , Naser, Sofia , Divard, Gillian , Aubert, Olivier , Murad, M Hassan , Liu, Longshan , Bestard, Oriol , Naesens, Maarten , Friedewald, John J , Lefaucheur, Carmen , Riella, Leonardo V , Collins, Gary , Ioannidis, John P A , Loupy, Alexandre , Bello, Arnaud Del , Divard, Gillian , Murad, M. Hassan , Bestard, Oriol , Naesens, Maarten , Friedewald, John J. , Ioannidis, John P. A. , Loupy, Alexandre

Mayo Clinic

Journal of the American Society of Nephrology | December 6, 2023 | Volume: 35 | Issue: 2 | Pages: 177-188

10.1681/asn.0000000000000260 | PMID 38053242 Get It

Significance Statement Why are there so few biomarkers accepted by health authorities and implemented in clinical practice, despite the high and growing number of biomaker studies in medical research ? In this meta-epidemiological study, including 804 studies that were critically appraised by expert reviewers, the authors have identified all prognostic kidney transplant biomarkers and showed overall suboptimal study designs, methods, results, interpretation, reproducible research standards, and transparency. The authors also demonstrated for the first time that the limited number of studies challenged the added value of their candidate biomarkers against standard-of-care routine patient monitoring parameters. Most biomarker studies tended to be single-center, retrospective studies with a small number of patients and clinical events. Less than 5% of the studies performed an external validation. The authors also showed the poor transparency reporting and identified a data beautification phenomenon. These findings suggest that there is much wasted research effort in transplant biomarker medical research and highlight the need to produce more rigorous studies so that more biomarkers may be validated and successfully implemented in clinical practice. Background Despite the increasing number of biomarker studies published in the transplant literature over the past 20 years, demonstrations of their clinical benefit and their implementation in routine clinical practice are lacking. We hypothesized that suboptimal design, data, methodology, and reporting might contribute to this phenomenon. Methods We formed a consortium of experts in systematic reviews, nephrologists, methodologists, and epidemiologists. A systematic literature search was performed in PubMed, Embase, Scopus, Web of Science, and Cochrane Library between January 1, 2005, and November 12, 2022 (PROSPERO ID: CRD42020154747). All English language, original studies investigating the association between a biomarker and kidney allograft outcome were included. The final set of publications was assessed by expert reviewers. After data collection, two independent reviewers randomly evaluated the inconsistencies for 30% of the references for each reviewer. If more than 5% of inconsistencies were observed for one given reviewer, a re-evaluation was conducted for all the references of the reviewer. The biomarkers were categorized according to their type and the biological milieu from which they were measured. The study characteristics related to the design, methods, results, and their interpretation were assessed, as well as reproducible research practices and transparency indicators. Results A total of 7372 publications were screened and 804 studies met the inclusion criteria. A total of 1143 biomarkers were assessed among the included studies from blood ( n =821, 71.8%), intragraft ( n =169, 14.8%), or urine ( n =81, 7.1%) compartments. The number of studies significantly increased, with a median, yearly number of 31.5 studies (interquartile range [IQR], 23.8–35.5) between 2005 and 2012 and 57.5 (IQR, 53.3–59.8) between 2013 and 2022 ( P < 0.001). A total of 655 studies (81.5%) were retrospective, while 595 (74.0%) used data from a single center. The median number of patients included was 232 (IQR, 96–629) with a median follow-up post-transplant of 4.8 years (IQR, 3.0–6.2). Only 4.7% of studies were externally validated. A total of 346 studies (43.0%) did not adjust their biomarker for key prognostic factors, while only 3.1% of studies adjusted the biomarker for standard-of-care patient monitoring factors. Data sharing, code sharing, and registration occurred in 8.8%, 1.1%, and 4.6% of studies, respectively. A total of 158 studies (20.0%) emphasized the clinical relevance of the biomarker, despite the reported nonsignificant association of the biomarker with the outcome measure. A total of 288 studies assessed rejection as an outcome. We showed that these rejection studies shared the same characteristics as other studies. Conclusions Biomarker studies in kidney transplantation lack validation, rigorous design and methodology, accurate interpretation, and transparency. Higher standards are needed in biomarker research to prove the clinical utility and support clinical use.
Clostridioides difficile infection in solid organ and hematopoietic stem cell transplant recipients: A prospective multinational study
Blumberg, Emily A. , Collins, Gary , Young, Jo‐Anne H. , Michonneau, David , Temesgen, Zelalem , Origüen, Julia , Barcán, Laura , Obeid, Karam M. , Belloso, Waldo , Corbelli, Giulio Maria , Neaton, James D. , Lundgren, Jens , Molina, Jean‐Michel , Group, for the INSIGHT Clostridioides difficile Study, Michonneau, David , Temesgen, Zelelem , Obeid, Karam M , Belloso, Waldo H , Gras, Julien , Corbelli, Giulio Maria , Lundgren, Jens , Snydman, D R , Young, Jo-Anne H , Nguyen, M Hong , Snydman, David R. , Group, for the INSIGHT Clostridioides difficile Study

Mayo Clinic

Transplant Infectious Disease | November 25, 2021 | Volume: 24 | Issue: 1 | Pages: No page available

10.1111/tid.13770 | PMID 34821423 Get It

AbstractBackgroundClostridioides difficile infection (CDI) is a significant cause of morbidity and mortality in recipients of solid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT). In retrospective single center analyses, severe disease and relapse are common. We undertook an international, prospective cohort study to estimate the response to physician determined antibiotic treatment for CDI in patients with SOT and HSCT.MethodsAdults with a first episode of CDI within the first 2 years of SOT or HSCT were enrolled. Demographics, comorbidities, and medication history were collected, and over 90 days of follow‐up clinical cure, recurrences, and complications were assessed. Logistic regression was used to study associations of baseline predictors of clinical cure and recurrence. Odds ratios (ORs) and 95% confidence intervals (CIs) are cited.ResultsA total of 132 patients, 81 SOT and 51 HSCT (32 allogeneic), were enrolled with a median age of 56 years; 82 (62%) were males and 128 (97%) were hospitalized at enrollment. One hundred and six (80.3%) were diagnosed by DNA assay. CDI occurred at a median of 20 days post‐transplant (interquartile range, IQR: 6–133). One hundred and eight patients (81.8%) were on proton pump inhibitors; 126 patients (95.5%) received antibiotics within the 6 weeks before CDI. The most common initial CDI treatments prescribed, on or shortly before enrollment, were oral vancomycin alone (50%) and metronidazole alone (36%). Eighty‐three percent (95% CI: 76, 89) of patients had clinical cure; 18% (95% CI: 12, 27) of patients had recurrent CDI; global clinical cure occurred in 65.2%. Of the 11 patients who died, two (1.5% of total) were related to CDI. In multivariable logistic regression analyses, the type of initial treatment was associated with clinical cure (p = .009) and recurrence (p = .014). A history of cytomegalovirus (CMV) after transplant was associated with increased risk of recurrence (44% with versus 13% without CMV history; OR: 5.7, 95% CI: 1.5, 21.3; p = .01).ConclusionsAmong adults who develop CDI after SOT or HSCT, despite their immunosuppressed state, the percentage with clinical cure was high and the percentage with recurrence was low. Clinical cure and recurrence varied by type of initial treatment, and CMV viremia/disease was associated with an increased risk of recurrence.
Short Communication: A Pilot Study of the Effects of Losartan Versus Placebo on Pneumoproteins in HIV: A Secondary Analysis of a Randomized Double Blind Study
MacDonald, David M. , Collins, Gary, Wendt, Chris H., Wolfson, Julian, Tracy, Russell P., Rhame, Frank, Deeks, Steven, Rizza, Stacey A., Temesgen, Zelalem, Morse, Caryn, Liappis, Angelike P., Sereti, Irini, Baker, Jason V., Kunisaki, Ken M., Baker, Jason V. , Wendt, Chris H. , Kunisaki, Ken M. , Wendt, Chris H , Wolfson, Julian , Kunisaki, Ken M , MacDonald, David M. , Collins, Gary, Wolfson, Julian , Tracy, Russell P., Rhame, Frank, Deeks, Steven, Rizza, Stacey A., Temesgen, Zelalem, Morse, Caryn, Liappis, Angelike P., Sereti, Irini, Baker, Jason V.

Mayo Clinic

AIDS Research and Human Retroviruses | March 22, 2021 | Volume: 38 | Issue: 2 | Pages: 127-130

10.1089/aid.2020.0285 | PMID 33749317 Get It

HIV is an independent risk factor for lung disease, including chronic obstructive pulmonary disease (COPD) and emphysema. Angiotensin receptor blockers may be beneficial in COPD and emphysema through pathways that have been implicated in HIV-related lung disease. We performed a randomized comparison of the effects of losartan versus placebo on the plasma concentrations of the pneumoproteins, surfactant protein D (SPD) and club cell secretory protein (CCSP), in people living with HIV (PLWH). A total of 108 PLWH were included (52 assigned to losartan and 56 assigned to placebo). We found no difference in the change from baseline in log 2 concentrations of CCSP or SPD over 1 year of follow-up. For SPD, we found a strong interaction by CD4+ counts, where those with CD4+ counts >350 cells/mm 3 treated with losartan had more reduction (improvement) in SPD concentration than those treated with placebo ( p value for interaction <.001). In conclusion, we did not find a beneficial effect of losartan on pneumoprotein concentrations in PLWH, but PLWH with higher CD4+ counts may have improvement in SPD when treated with losartan.
Losartan to reduce inflammation and fibrosis endpoints in HIV disease
Baker, Jason V. , Collins, Gary, Morse, Caryn G. , Rhame, Frank S., Liappis, Angelike P., Rizza, Stacey A. , Temesgen, Zelalem , Mystakelis, Harry , Neaton, James D. , Schacker, Timothy W. , Rizza, Stacey , Wolfson, Julian , Wolfson, Julian , Deeks, Steven G. , Sereti, Irini , Tracy, Russell P.

Mayo Clinic

AIDS | November 29, 2020 | Volume: 35 | Issue: 4 | Pages: 575-583

10.1097/qad.0000000000002773 | PMID 33252490 Get It

Background: Persistent inflammation and incomplete immune recovery among persons with HIV (PHIV) are associated with increased disease risk. We hypothesized that the angiotensin receptor blocker (ARB) losartan would reduce inflammation by mitigating nuclear factor (NF)κB responses and promote T-cell recovery via inhibition of transforming growth factor-beta (TGFβ)-mediated fibrosis. Methods: Losartan (100 mg) versus placebo over 12 months was investigated in a randomized (1 : 1) placebo-controlled trial, among PHIV age at least 50 years, receiving antiretroviral therapy (ART), with HIV RNA less than 200 copies/ml and CD4+ cell count 600 cells/μl or less. Inflammation, fibrosis and myocardial biomarkers were measured in blood using ELISA, electrochemiluminescence and immunoturbidimetric methods, and T-cell and monocyte phenotypes were assessed with flow cytometry among a subset of participants. Changes over follow-up in (log-2 transformed) biomarkers and cell phenotypes (untransformed) were compared between losartan and placebo arms using linear mixed models. Results: Among 108 PHIV (n = 52 to losartan; n = 56 to placebo), 97% had a month 12 visit. Median age was 57 years and baseline CD4+ cell count was 408 cells/μl. Losartan treatment was not associated with an improvement in interleukin-6 levels, or other blood measures of inflammation, immune activation, fibrosis activity or myocardial function. CD4+ and CD8+ T cells also did not differ by treatment group. Losartan reduced SBP and DBP by 6 and 5 mmHg, respectively. Conclusion: Among older PHIV with viral suppression, losartan did not improve blood measures of inflammation nor T-cell immune recovery. Losartan treatment is unlikely to reduce inflammation associated comorbidities to a clinically meaningful degree, beyond the benefits from lowering blood pressure. ClinicalTrials.gov: NCT02049307.
Effects of Losartan vs. Placebo on Pulmonary Biomarkers in HIV: A Randomized Comparison
Collins, Gary, Wendt, Christine , Rhame, Frank S., Rizza, Stacey A. , Zelalem, T., Liappis, Angelike P., Irini, S., MacDonald, David M. , Baker, Jason V. , Wolfson, Julian , Tracy, Russell P. , Deeks, Steven G. , Morse, Caryn G. , Kunisaki, Ken M.

Mayo Clinic

A108. HIV RELATED PNEUMONIA, TB, AND MYCOBACTERIAL INFECTIONS | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A2697-A2697

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a2697 Get It

2670. Clostridioides difficile Infection (CDI) in Solid-Organ (SOT) and Hematopoietic Stem Cell Transplant (HCT) Recipients: A Prospective Multinational Study
Collins, Gary, Temesgem, Zelalem, Barcán, Laura , Belloso, Waldo , Corbelli, Giulio Maria , Neaton, James, Blumberg, Emily A. , Young, Jo‐Anne H. , Nguyen, M Hong , Michonneau, David , Origüen, Julia , Obeid, Karam M. , Gras, Julien , Neaton, James D. , Lundgren, Jens , Snydman, David R. , Molina, Jean‐Michel

Mayo Clinic

Open Forum Infectious Diseases | October 23, 2019 | Volume: 6 | Issue: Supplement_2 | Pages: S936-S936

10.1093/ofid/ofz360.2348 Get It

Abstract Background CDI is an important cause of morbidity and mortality in SOT and HCT patients (pts). In retrospective single-center analyses, severe disease and relapse were common. We undertook a multicenter prospective observational study to evaluate outcomes of CDI among both SOT and HCT patients. Methods Adults with a first episode of CDI, defined as 3 liquid stools/24 h with the detection of C. difficile toxin in stool, within the first 2 years of SOT or HCT were recruited from 12 centers internationally in the INSIGHT network. At enrollment, demographics, comorbidities, medication histories and outcomes were collected prospectively over 90 days to assess clinical cure, recurrences and complications and to define baseline risk factors for clinical cure and recurrent CDI. Results 132 patients (81 SOT, 51 HCT (32 allogeneic)) were enrolled: median age 56 years, 62.1% were males, 97% were hospitalized. 80.3% were diagnosed by DNA assay. CDI occurred a median of 20 days post transplant (IQR: 6–133). 108 patients were on PPIs. 98.5% were on antibiotics before CDI. 1st line treatment regimen was oral vancomycin in 66 patients (40 SOT, 26 HCT), metronidazole in 48 patients (27 SOT, 21 HCT), both drugs in 14 (10 SOT, 4 HCT), fidaxomicin (3) and linezolid (1). Rejection within 60 days before CDI was uncommon (6.2% SOT) as was GVHD (27.5%). 110 patients (83%, 95% CI: 46–89)) (65 SOT, 45 HCT) had clinical cure; 18% (95% CI: 11–27) had recurrent CDI, 2 were admitted to the ICU due to CDI, 11 (8.3%) died (2 HCT related to CDI). Among baselines variables, only first-line regimen was associated with a higher rate of clinical cure (P = 0.003), most notably for SOT. Factors that did not have a statistically significant negative impact on clinical cure included sex, age > 60, race, country, transplant type, steroids, diabetes, CMV viremia/disease, WBC > 15,000, creatinine > 1.5 mg/dL, or specific antibiotic given prior to CDI. Higher recurrence rates were associated with metronidazole-only regimen (OR: 4.6, 95% CI: 1.6–12.8; P = 0.004) and a history of CMV after transplant (OR: 5.2, 95% CI: 1.7–15.7; P = 0.003). Conclusion Despite their immunosuppressed state, recurrence, ICU admission and mortality occurred in a minority of SOT and HCT with CDI. Initial use of metronidazole and CMV viremia/disease were associated with higher recurrence rates. Disclosures All authors: No reported disclosures.